Home › Neoplasie mieloproliferative › Texas › Houston
Studi clinici su Neoplasie mieloproliferative a Houston, TX
16 studi su Neoplasie mieloproliferative cercano partecipanti presso sedi a Houston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
In reclutamentoFase 1
- The University of Texas, MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
In reclutamentoStudio osservazionale
- Texas Children's Hospital, Houston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
In reclutamentoFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
In reclutamentoFase 1/2
- MD Anderson, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
In reclutamentoFase 1
- M D Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
In reclutamentoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
In reclutamentoFase 1/2
- M D Anderson Cancer Center, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
In reclutamentoFase 2
- M D Anderson Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
In reclutamentoStudio osservazionale
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
In reclutamentoFase 1
- University of Texas M. D. Anderson Cancer Center, Houston
Asciminib Roll-over Study
In reclutamentoFase 4
- Uni Of TX MD Anderson Cancer Cntr, Houston
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
In reclutamentoFase 2
- M D Anderson Cancer Center, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
In reclutamentoFase 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
In reclutamentoFase 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
In reclutamentoFase 1
- The University of Texas MD Anderson Cancer Center, Houston
Studi su Neoplasie mieloproliferative in altre città
- New York City, NY15 studi
- Boston, MA14 studi
- Milwaukee, WI10 studi
- Miami, FL10 studi
- Chicago, IL9 studi
- Durham, NC9 studi
- Baldwin Park, CA9 studi
- Seattle, WA9 studi
- Atlanta, GA8 studi
- Tampa, FL8 studi
- Birmingham, AL8 studi
- Columbus, OH8 studi
Altri studi a Houston
- Cancro del polmone non a piccole cellule145 studi
- Cancro al seno126 studi
- Cancro (tutti i tipi)121 studi
- Cancro metastatico104 studi
- Cancro colorettale102 studi
- Cancro ovarico89 studi
- Leucemia mieloide acuta85 studi
- Cancro ai polmoni78 studi
- Cancro alla prostata76 studi
- Cancro dell'endometrio68 studi
- Cancro pancreatico61 studi
- Melanoma59 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.